Cardiology Research and Practice

Research Article

Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background

Table 1

Baseline characteristics of study population.
Variable
Age (yrs) 6 3 . 2 ± 9
Male gender 𝑛 (%)107 (82)
NYHA functional class 2 . 2 ± 0 . 7
SBP (mm Hg) 1 2 7 ± 1 5
DBP (mm Hg) 7 9 ± 8
Heart Rate (beats/min) 6 7 ± 1 1
S-Na+ (mEq/L) 1 3 9 ± 3
S-Creatinine (μmol/L) 1 0 5 ± 2 5
Hb (g/dL) 1 3 . 9 ± 1 . 3
Treatment 𝑛 (%)
 Diuretics117 (90)
 ACE inhibitors/ARBs127 (97)
 Beta blockers110 (84)
 Spironolactone31 (24)
 Statins90 (69)
Echocardiography
 LVEF (%) 3 3 ± 7
 LVEDV (mL) 2 6 6 ± 9 8
 LVESV (mL) 1 8 1 ± 8 6
Genotypes, 𝑛
 ACE II/ ID, DD20/111
 β1 AR389 ≥1 Arg/GlyGly31/100
 β2 16 GlyGly/ ≥ 1 Arg57/74
 β2 27 GlnGln/ ≥ 1 Glu51/80
Data are expressed as mean ± SD or number (%). Abbreviations: NYHA: New York Heart Association; SBP: systolic blood pressure; DBP: diastolic blood pressure; Hb: hemoglobin; ARBs: angiotensin II receptor blockers; LVEF: left ventricular ejection fraction; LVEDV: left ventricular end diastolic volume; LVESV: left ventricular end systolic volume.